Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584959 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
NCT02584959 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 75 participants.
The verdict
NCT02584959, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of subcutaneous administration of a liquid formulation of C1 esterase inhibitor for the prevention of angioedema attacks in adolescent and adult subjects with hereditary angioedema.
Interventions
- DRUG Placebo
- DRUG C1 esterase inhibitor [human] liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2017-07-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584959
The ClinicalTrials.gov registry entry for NCT02584959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02584959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584959 about?
NCT02584959 is a clinical study titled "Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema". The purpose of this study is to assess the efficacy and safety of subcutaneous administration of a liquid formulation of C1 esterase inhibitor for the prevention of angioedema attacks in adolescent and adult subjects with hereditary angioedema.
What is the current status of trial NCT02584959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2015-11-01. Estimated completion is 2017-07-24.
What interventions are being tested in trial NCT02584959?
The interventions under investigation include: Placebo (DRUG), C1 esterase inhibitor [human] liquid (DRUG).
Who is sponsoring clinical trial NCT02584959?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.